title: Comparison of outcomes of trabeculectomy with mitomycin C vs. ologen implant in primary glaucoma.
abstract: OBJECTIVE
  To compare the safety and efficacy of trabeculectomy with Ologen implant vs. trabeculectomy with Mitomycin C (MMC).
  
  
  METHODS
  In a prospective, randomized, pilot study, 39 eyes of 33 subjects with medically uncontrolled primary glaucoma, aged 18 years or above underwent trabeculectomy either with MMC (20 eyes) or with Ologen implant (19 eyes). The primary outcome measure was cumulative success probability, defined as complete if the intraocular pressure (IOP) was > 5 and ≤ 21 mm Hg without anti-glaucoma medications or additional surgery and qualified if an IOP was > 5 and ≤ 21 mm Hg with or without anti-glaucoma medications.
  
  
  RESULTS
  Mean (± standard deviation) follow-up in Ologen group was 19.1 ± 8.1 months, and in MMC group was 18.0 ± 8.4 months. Mean IOP reduction at 6 months was significantly lower (P = 0.01) in the MMC group (11.9 ± 2.9 mm Hg) as compared to Ologen group (14.6 ± 2.7 mm Hg). However, at 12 months (P = 0.81) and 24 months (P = 0.32), the mean IOP was similar between the 2 groups. Complete success probability at the end of 6 months in Ologen group was 100% (95% confidence interval: 59.1 - 99.0) was similar (P = 0.53) to that in MMC group (93.8%, 95% CI: 63.2 - 99.1). The incidences of early post-operative complications were similar in the 2 groups, except hyphema, which was significantly more in Ologen group (P = 0.02).
  
  
  CONCLUSIONS
  In this pilot study, the success of trabeculectomy and complications were similar in both Ologen and MMC groups at the end of 6 months.
authors.affiliation: VST Glaucoma Center, L.V Prasad Eye Institute, Kallam Anji Reddy Campus, Banjara Hills, Hyderabad, India.
authors.forename: Sirisha
authors.initials: S
authors.lastname: Senthil
authors.forename: Harsha L
authors.initials: HL
authors.lastname: Rao
authors.forename: Jonnadula G
authors.initials: JG
authors.lastname: Babu
authors.forename: Anil K
authors.initials: AK
authors.lastname: Mandal
authors.forename: Chandra Sekhar
authors.initials: CS
authors.lastname: Garudadri
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D003094:Collagen / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000503:physiopathology / Q000628:therapy*; D006025:Glycosaminoglycans / Q000008:administration & dosage*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D010865:Pilot Projects; D011108:Polymers; D011446:Prospective Studies; D014130:Trabeculectomy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D004343:Drug Implants; D006025:Glycosaminoglycans; D011108:Polymers; C058506:collagen-glycosaminoglycan copolymer; D016685:Mitomycin; D003094:Collagen